MIRM
Mirum Pharmaceuticals, Inc.
Key Financials
Net Income
$-23363000
↑ 73.4%
Operating Income
$-22136000
↑ 74.7%
Revenue
$521.3M
↑ 54.7%
Total Liabilities
$528.1M
↑ 18.6%
EPS (Diluted)
$-0.47
↑ 74.6%
Total Assets
$842.8M
↑ 25.7%
Cash & Equivalents
$296.7M
↑ 33.3%
Shareholders' Equity
$314.7M
↑ 39.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 4/16/2026 | View on SEC |
| 144 | 4/15/2026 | View on SEC |
| 8-K/A | 4/8/2026 | View on SEC |
| SCHEDULE 13G/A | 3/27/2026 | View on SEC |
| 4 | 3/17/2026 | View on SEC |
| 4 | 3/17/2026 | View on SEC |
| 4 | 3/17/2026 | View on SEC |
| 4 | 3/17/2026 | View on SEC |
| 4 | 3/17/2026 | View on SEC |
| 4 | 3/17/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | MIRM |
| Company Name | Mirum Pharmaceuticals, Inc. |
| CIK | 1759425 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650-667-4085 |